ERRATUM

Erratum on “Non-indolent mantle cell lymphoma at a single public hospital in Brazil: real world first-line treatment cohort study data”

Sergio Augusto Buzian Brasil ∗, Carolina Colaço, Tomás Barrese, Roberto P. Paes, Cristina Bortolheiro, Rodolfo Delfini Cançado

Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil

In the article “Non-indolent mantle cell lymphoma at a single public hospital in Brazil: real world first-line treatment cohort study data”, with DOI number: http://dx.doi.org/10.1016/j.htct.2018.12.003, published in Hematol Transfus Cell Ther. 2020;42(1):93–97, Figure 2 is duplicated, therefore, where it reads:

“The SCG and NSCG overall survival were 12 months and 9.6 months, respectively, and these data were not statistically significant (Figures 2 and 3).”

It should read:

“In comparison, the SCG and NSCG overall survival results were not statistically significant, which means that with the disposable chemotherapy armamentarium, whatever efforts we make, the results are quite the same, regardless of patient fitness or age (Figure 3).”

And where it reads:

“In comparison, the SCG and NSCG overall survival results were not statistically significant, which means that with the disposable chemotherapy armamentarium, whatever efforts we make, the results are quite the same, regardless of patient fitness or age (Figure 2).”

DOI of original article: https://doi.org/10.1016/j.htct.2018.12.003.

* Corresponding author. Rua Guaraciara n° 12, Planalto Paulista, CEP: 04082040, São Paulo, SP, Brazil
E-mail address: sbbrasil62@gmail.com (S.A. Brasil).

https://doi.org/10.1016/j.htct.2020.04.004

2531-1379/© 2019 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).